Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
124 hedge funds and large institutions have $1.93B invested in Sage Therapeutics in 2015 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 53 increasing their positions, 17 reducing their positions, and 17 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
212% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 17
188% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 17
78% more capital invested
Capital invested by funds: $1.08B → $1.93B (+$847M)
35% more funds holding
Funds holding: 92 → 124 (+32)
68% less call options, than puts
Call options by funds: $3.23M | Put options by funds: $10.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$59.7M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$58.3M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$48.7M |
| 4 |
VAM
Visium Asset Management
New York
|
+$40.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$26.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$64.3M |
| 2 |
DM
Deerfield Management
New York
|
-$18.7M |
| 3 |
O
OrbiMed
New York
|
-$16.9M |
| 4 |
Millennium Management
New York
|
-$8.89M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$7.94M |
SAGE Hedge Fund Activity: Q2 2015 in Review
124 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2015, worth a combined $1.93B — up 78% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new SAGE positions and 17 closed out — a net gain of 32 holders — while 53 added to existing stakes and 17 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, opening a new position worth an estimated $59.7M. The largest seller was Third Rock Ventures, cutting an estimated $64.3M.
- 124 institutional investors held Sage Therapeutics (SAGE) as of Q2 2015, up from 92 in Q1 2015.
- Funds reported $1.93B of Sage Therapeutics stock for Q2 2015, up 78% quarter-over-quarter.
- 49 funds opened new Sage Therapeutics positions in Q2 2015 and 17 closed out, a net change of +32 holders.
- The largest Sage Therapeutics buyer in Q2 2015 was Gilder Gagnon Howe & Co, an estimated $59.7M added.
- The largest Sage Therapeutics seller in Q2 2015 was Third Rock Ventures, an estimated $64.3M sold.
Based on aggregated 13F filings for Q2 2015.